Market Overview

ARCA Biopharma Announces Clinical Trial Agreement for GENETIC-AF Trial


ARCA biopharma (NASDAQ: ABIO) and Duke University's Duke Clinical Research Institute (DCRI), the
world's largest academic clinical research organization (ARO), today
announced a new agreement under which ARCA and the DCRI will work
together to execute GENETIC-AF, a planned Phase 2B/3
genetically-targeted, comparative effectiveness clinical trial
evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment
for the prevention of atrial fibrillation (AF) in patients with heart
failure. Patient enrollment in GENETIC-AF is expected to begin in the
first quarter of 2014.

ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABIO)

View Comments and Join the Discussion!

Partner Center